Navigation Links
Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells
Date:7/10/2014

Cleveland, Ohio (PRWEB) July 10, 2014

Understanding the need for better quality and higher consistency in ion channel-expressing cell lines, and the gap that currently exists in this area, ChanTest has recently developed new cells that expand its industry-leading portfolio of validated ion channel and GPCR cell lines. ChanTest’s research focuses on ion channel-expressing cell lines, as ion channels control many critical physiological functions throughout the body. Being able to control this activity creates the potential to treat a variety of human diseases.

ChanTest has validated these cells using their automated electrophysiology and fluorescent plate reader systems.

Because of their control over many critical physiological functions, ion channels are one of the most important categories of drug targets in the pharmaceutical industry. With the growing need to test the safety and efficiency of new drugs, the importance of an organized library of cell lines is critical.

ChanTest’s cell and molecular biology group has developed several new or improved recombinant cells expressing ligand-gated ion channels. Two of these new products, CTN6117 (stably transfected) and CTN7117 (transiently transfected), consist of ionotropic serotonergic (5-HT3A) receptors expressed in HEK293 cells. 5-HT3A is a therapeutic target in nausea and irritable bowel syndrome. Also, new cell lines have been developed that stably express nicotinic acetylcholine receptor subtypes in CHO cells. These include a3ß4a5 (CT6024) and a2ß4 (CT6023), which are important therapeutic targets in several neurological indications, and join previously developed nicotinic a7 (CT6201) and a3ß4 (CT6021) subtype-expressing cell lines in our catalog. ChanTest has engineered all cells for optimal performance in automated patch clamp and FLIPR high throughput screening systems.

In combination with automated medium- to high-throughput functional assays, ChanTest can help organizations rapidly profile compounds across a range of ion channels. ChanTest can also help to construct and validate other cell lines in a timely and cost effective manner.

For a complete list of available cell lines, visit: http://www.chantest.com/reagents/ion-channel/cell-lines.

About ChanTest® – The Ion Channel Expert

ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide. Since its start in 1998, the Contract Research Organization has tested compounds for more than 300 global pharmaceutical and biotechnology companies. ChanTest also partners with these companies to accelerate the drug development process for the release of better, safer drugs. ChanTest offers ion channel and GPCR cell reagents, ion channel screening/profiling services, and cardiac safety services. The company’s library of validated ion channel cell lines, and nonclinical cardiac risk assessment service portfolio, is the most comprehensive commercial library available today.

Because of ChanTest’s influential role, along with the company’s uncompromising commitment to quality, an independent survey has named ChanTest the “most trusted and most used fee-for-service provider” since 2006. ChanTest is based in Cleveland, Ohio.

Visit http://www.chantest.com to learn more about ChanTest.

FURTHER INFORMATION

ChanTest
14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
1-216-332-1665 Tel
1-216-332-1706 Fax
info(at)chantest(dot)com

Contact for Media Inquiries:

Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer
cmathes(at)chantest(dot)com
http://www.chantest.com

Read the full story at http://www.prweb.com/releases/2014/07/prweb12003806.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
2. Leaders in Science Join Upcoming Celebration of the 100th Anniversary of the Oldest Science Foundation in America
3. Sweet Success for Hosmac India Pvt. Ltd. at ET NOW-IndiaMART Leaders of Tomorrow Awards 2011
4. Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology
5. Berkeley Lab seeks to help US assert scientific leadership in critical materials
6. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
7. Auxilium Announces Appointments to Enhance Leadership Team
8. Global Leaders in Advanced Biofuels Industry Urge Congressional Leaders to Extend Critical Tax Provisions
9. DuPont Leader Overviews 2012 Seed Research Pipeline with Investors
10. More than half of Americans doubt US global leadership in 2020
11. USC Marshall School of Business 6th Annual Leadership Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):